Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Csanaky, I.
Right arrow Articles by Gregus, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Csanaky, I.
Right arrow Articles by Gregus, Z.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 63, 29-36 (2001)
Copyright © 2001 by the Society of Toxicology


BIOTRANSFORMATION AND TOXICOKINETICS

Effect of Phosphate Transporter and Methylation Inhibitor Drugs on the Disposition of Arsenate and Arsenite in Rats

Iván Csanaky and Zoltán Gregus,1

Department of Pharmacology and Pharmacotherapy, University of Pécs, Medical School, Pécs, Hungary

Arsenate (AsV) is biotransformed into the more toxic arsenite (AsIII) and monomethylarsonous acid (MMAsIII), but it is unknown how to decrease production of these harmful metabolites. We investigated the effects of foscarnet and fosfomycin, drugs interacting with the phosphate transporter, on biotransformation of AsV, an analog of inorganic phosphate. The effects of entacapone, an inhibitor of catechol-O-methyl transferase (COMT), and nitrous oxide, an inactivator of methylcobalamin, were also tested on the formation of MMAsIII from AsIII in order to clarify the role of COMT and methylcobalamin in biomethylation of AsIII. Arsenic in bile and urine of control and treated rats receiving AsV or AsIII was speciated by HPLC-HG-AFS. In AsV-injected rats, foscarnet, but not fosfomycin, increased the urinary excretion of AsV and decreased the biliary and urinary excretion of AsIII as well as biliary excretion of MMAsIII. In AsIII-injected rats, however, foscarnet failed to influence the excretion of AsIII and its metabolites, suggesting that this drug inhibits the hepatic uptake and renal reabsorption of AsV, thereby decreasing formation of AsIII and MMAsIII from AsV. Entacapone or nitrous oxide pretreatment slightly or not at all influenced the biliary excretion of MMAsIII and urinary excretion of dimethylarsinic acid (DMAsV) in AsIII-injected rats. In contrast, periodate-oxidized adenosine, an inhibitor of S-adenosylmethionine-dependent methyltransferases, nearly abolished appearance of methylated arsenic metabolites in bile and urine. Thus, foscarnet facilitates urinary clearance of AsV and decreases formation of toxic AsIII and MMAsIII, indicating that this drug may be used to promote elimination and counter toxification of AsV. Because entacapone and nitrous oxide influenced the excretion of MMAsIII and DMAsV negligibly, neither COMT nor methylcobalamin appears to be involved in arsenic methylation in rats.

Key Words: arsenic; monomethylarsonous acid; foscarnet (fosfonoformic acid); fosfomycin; entacapone; nitrous oxide (N2O); methylation; catechol-O-methyltransferase (COMT); methylcobalamin; biliary excretion; urinary excretion.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Toxicol SciHome page
C. D. Klaassen and H. Lu
Xenobiotic Transporters: Ascribing Function from Gene Knockout and Mutation Studies
Toxicol. Sci., February 1, 2008; 101(2): 186 - 196.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
B. Nemeti, I. Csanaky, and Z. Gregus
Effect of an Inactivator of Glyceraldehyde-3-Phosphate Dehydrogenase, a Fortuitous Arsenate Reductase, on Disposition of Arsenate in Rats
Toxicol. Sci., March 1, 2006; 90(1): 49 - 60.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
B. Nemeti and Z. Gregus
Reduction of Arsenate to Arsenite by Human Erythrocyte Lysate and Rat Liver Cytosol - Characterization of a Glutathione- and NAD-Dependent Arsenate Reduction Linked to Glycolysis
Toxicol. Sci., June 1, 2005; 85(2): 847 - 858.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
B. Nemeti and Z. Gregus
Glutathione-Dependent Reduction of Arsenate in Human Erythrocytes--a Process Independent of Purine Nucleoside Phosphorylase
Toxicol. Sci., December 1, 2004; 82(2): 419 - 428.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
B. Nemeti, I. Csanaky, and Z. Gregus
Arsenate Reduction in Human Erythrocytes and Rats--Testing the Role of Purine Nucleoside Phosphorylase
Toxicol. Sci., July 1, 2003; 74(1): 22 - 31.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
M. P. Waalkes and J. Liu
Purine Nucleoside Phosphorylase: A Fortuitous Cytosolic Arsenate Reductase?
Toxicol. Sci., November 1, 2002; 70(1): 1 - 3.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
B. Nemeti and Z. Gregus
Reduction of Arsenate to Arsenite in Hepatic Cytosol
Toxicol. Sci., November 1, 2002; 70(1): 4 - 12.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.